Close Menu

This article has been updated to note that atezolizumab is approved in the US for first-line metastatic bladder cancer and that the confirmatory study, IMvigor211, did not meet its primary endpoint rather than the IMvigor 210 trial as previously reported.

NEW YORK – Roche said on Monday it will withdraw the indication of atezolizumab (Tecentriq) in previously treated bladder cancer after a review of accelerated approvals by the US Food and Drug Administration.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.